Eli Lilly (LLY)

1,109.19
+7.11 (0.65%)
NYSE· Last Trade: Jun 23rd, 4:01 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,102.08
Open1,117.00
Bid1,109.13
Ask1,109.50
Day's Range1,079.22 - 1,122.02
52 Week Range623.78 - 1,182.73
Volume2,343,996
Market Cap1.06T
PE Ratio (TTM)48.33
EPS (TTM)22.9
Dividend & Yield6.920 (0.62%)
1 Month Average Volume3,303,167

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circlebenzinga.com
Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.
Via Benzinga · June 23, 2026
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?fool.com
The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.
Via The Motley Fool · June 23, 2026
3 Monster Stocks to Hold for the Next 10 Yearsfool.com
These healthcare stocks may be the building blocks of a winning portfolio.
Via The Motley Fool · June 23, 2026
2 Underrated Weight Loss Stocks to Buy and Holdfool.com
They look well-positioned to grab a slice of the fast-growing anti-obesity market.
Via The Motley Fool · June 23, 2026
Eli Lilly & Co. (NYSE:LLY): A High-Growth Champion Aligned with Navellier's Proven Strategychartmill.com
Via Chartmill · June 22, 2026
Eli Lilly & Co (NYSE:LLY): A Dividend Growth Gem with Strong Fundamentalschartmill.com
Via Chartmill · June 19, 2026
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...
Via StockStory · June 22, 2026
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskfool.com
Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.
Via The Motley Fool · June 22, 2026
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend...
Via Newsfile · June 22, 2026
1 Vanguard Index Fund Could Turn $450 Per Month Into a $905,200 Portfolio That Pays $16,400 in Annual Dividend Incomefool.com
Young adults with median earnings can build sizable portfolios that pay a hefty amount of passive income by retirement.
Via The Motley Fool · June 22, 2026
13 Stocks Are Members of the $1 Trillion Club. Here's the Best Pick to Buy Right Now.fool.com
Want to really go big? One megacap stock offers an especially attractive risk-reward proposition.
Via The Motley Fool · June 22, 2026
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?fool.com
Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.
Via The Motley Fool · June 20, 2026
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?fool.com
Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.
Via The Motley Fool · June 20, 2026
Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant?fool.com
Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.
Via The Motley Fool · June 20, 2026
3 Penny Stocks Under $5 Backed by Real Revenue Growthmarketbeat.com
These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside
Via MarketBeat · June 20, 2026
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trendmarketbeat.com
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.
Via MarketBeat · June 20, 2026
3 Reasons to Buy Eli Lilly Stockfool.com
Despite several setbacks over the past year, the drugmaker marches on.
Via The Motley Fool · June 20, 2026
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.fool.com
These companies don't typically compete directly with one another, but that might change soon.
Via The Motley Fool · June 20, 2026
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Yearsbenzinga.com
Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 12.92% on an annualized basis producing an average annual ...
Via Benzinga · June 19, 2026
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Ownfool.com
AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience.
Via The Motley Fool · June 19, 2026
Market-Weighted Healthcare or Active Manager Selection? IYH vs. PINKfool.com
The iShares U.S. Healthcare ETF (IYH) tracks a broad healthcare index, while the Simplify Health Care ETF (PINK) gives an active manager more room to choose. That difference matters for investors deciding whether they want benchmark exposure or a more concentrated healthcare portfolio.
Via The Motley Fool · June 18, 2026
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com
After a few days of purging, the Ark Invest growth investor is buying stocks again.
Via The Motley Fool · June 18, 2026
3 Stocks Doing the Heavy Lifting in Healthcare’s Reboundmarketbeat.com
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.
Via MarketBeat · June 18, 2026
Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy?fool.com
Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals.
Via The Motley Fool · June 18, 2026
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors?fool.com
Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability.
Via The Motley Fool · June 17, 2026